Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 1:15:97-109.
doi: 10.2147/TACG.S370242. eCollection 2022.

Long Non-Coding RNAs ASB16-AS1 and AFAP1-AS1: Diagnostic, Prognostic Impact and Survival Analysis in Colorectal Cancer

Naglaa S Elabd  1 , Shimaa E Soliman  2 , Moamena S Elhamouly  1 , Suzy F Gohar  3 , Ayman Elgamal  4 , Mahmoud Magdy Alabassy  5 , Haitham A Soliman  5 , Abdelnaser A Gadallah  6 , Osama D Elbahr  7 , Ghada Soliman  3 , Amany A Saleh  2
Affiliations

Long Non-Coding RNAs ASB16-AS1 and AFAP1-AS1: Diagnostic, Prognostic Impact and Survival Analysis in Colorectal Cancer

Naglaa S Elabd et al. Appl Clin Genet. .

Abstract

Background: We aimed to evaluate the diagnostic roles of AFAP1-AS1 and ASB16-AS1 in colorectal cancer and highlight their roles in predicting colorectal cancer patients' prognosis.

Methods: In this case-control study, 146 participants were involved. Group I included 47 patients with CRC. Group II composed of 49 patients with benign lesions in the colon, and Group III included 50 apparently normal subjects of coincided age and gender as controls. All participants were subjected to clinical and endoscopic evaluations, CA19-9, CEA, and quantification of relative expression of lncRNAs ASB16-AS1 and AFAP1-AS1.

Results: CRC patients had significantly elevated expression levels of both lncRNAs in tissue and plasma samples versus benign and control groups (p < 0.001). Despite the higher sensitivity of tissue samples results, the relative expression of both lncRNAs in plasma samples was very encouraging in the discrimination between patients with CRC versus control and benign groups. Furthermore, both lncRNAs could discriminate patients with early-stage CRC (stage I&II) from being colonic lesion and control groups with better sensitivity and specificity presented by ASB16-AS1 in tissue and plasma than results detailed by AFAP1-AS1. High expression levels of ASB16-AS1 in tissue and plasma and tissue lncRNA AFAP1-AS1 are significantly correlated with decreased overall survival (p < 0.001) and reduced progression-free (p < 0.001) compared to low expression in CRC patients.

Conclusion: We propose the utilization of lncRNA ASB16-AS1 and lncRNA AFAP1-AS1 as biomarkers in diagnosis and prognosis estimation for CRC patients. Moreover, their value in early CRC patients may affect the assortment of target therapy and treatment protocols.

Keywords: CRC; expression; lncRNA; overall survival; progression-free survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Comparison between groups regarding lncRNA ASB16-AS1 and lncRNA AFAP1-AS1 expression levels and ROC curves for their diagnostic performance. (A) Comparison between early-stage CRC patients and benign group according to lncRNA ASB16-AS1 and lncRNA AFAP1-AS1 expression levels. *Significant between early CRC and Group II. (B) Comparison between early-stage CRC patients and controls according to the lncRNA ASB16-AS1 and lncRNA AFAP1-AS1 expression levels. *Significant between early CRC and Group III. (C) ROC curve for lncRNA ASB16-AS1, lncRNA AFAP1-AS1, CEA, and CA19-9 to discriminate CRC group from benign group. (D) ROC curve for lncRNA ASB16-AS1 and lncRNA AFAP1-AS1 to distinguish CRC group from the control group. (E) ROC curve for lncRNA ASB16-AS1 and lncRNA AFAP1-AS1to discriminate early stages CRC patients from benign group. (F) ROC curve lncRNA ASB16-AS1 and lncRNA AFAP1-AS1to discriminate early stages CRC patients and controls.
Figure 2
Figure 2
Correlation between studied lnRNA and CEA & CA19-9. (A) Correlation between tissue lncRNA ASB16-AS1 with CEA in CRC group. (B) Correlation between plasma lncRNA ASB16-AS1 with CEA in CRC group. (C) Correlation between tissue lncRNA ASB16-AS1 with CA19-9 in CRC group. (D) Correlation between plasma lncRNA ASB16-AS1 with CA19-9 in CRC group. (E) Correlation between tissue lncRNA AFAP1-AS1 with CA19-9 in CRC group.
Figure 3
Figure 3
Kaplan-Meier survival curve for overall survival and progression-free survival with studied lncRNA. (A) Kaplan-Meier survival curve for overall survival with tissue lncRNA ASB16-AS1. (B) Kaplan-Meier survival curve for overall survival with plasma lncRNA ASB16-AS1. (C) Kaplan-Meier survival curve for overall survival with tissue lncRNA AFAP1-AS1. (D) Kaplan-Meier survival curve for overall survival with plasma lncRNA AFAP1- AS1. (E) Kaplan-Meier survival curve for progression-free survival with tissue lncRNA ASB16-AS1. (F) Kaplan-Meier survival curve for progression-free survival with plasma lncRNA ASB16-AS1. (G) Kaplan-Meier survival curve for progression-free survival with tissue lncRNA AFAP1-AS1. (H) Kaplan-Meier survival curve for progression-free survival with plasma lncRNA AFAP1-AS1.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–691. doi:10.1136/GUTJNL-2015-310912 - DOI - PubMed
    1. Douaiher J, Ravipati A, Grams B, Chowdhury S, Alatise O, Are C. Colorectal cancer-global burden, trends, and geographical variations. J Surg Oncol. 2017;115(5):619–630. doi:10.1002/JSO.24578 - DOI - PubMed
    1. Ding X, Duan H, Luo H. Identification of core gene expression signature and key pathways in colorectal cancer. Front Genet. 2020;11:45. doi:10.3389/FGENE.2020.00045/BIBTEX - DOI - PMC - PubMed
    1. Sawicki T, Ruszkowska M, Danielewicz A, Niedźwiedzka E, Arłukowicz T, Przybyłowicz KE. A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. Cancers. 2021;13(9):2025. doi:10.3390/CANCERS13092025 - DOI - PMC - PubMed
    1. Marley AR, Nan H. Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet. 2016;7(3):105. doi:10.3109/9781420016307-2 - DOI - PMC - PubMed